FDA Approves Onivyde for Metastatic Pancreatic Cancer

Share this content:
FDA Approves Onivyde for Metastatic Pancreatic Cancer
FDA Approves Onivyde for Metastatic Pancreatic Cancer

FRIDAY, Oct. 23, 2015 (HealthDay News) -- The U.S. Food and Drug Administration has approved Onivyde (irinotecan liposome injection) to be used in combination with fluorouracil and leucovorin in advanced pancreatic cancer.

The approval was based on a study of 417 patients. All had experienced cancer growth despite gemcitabine-based chemotherapy. The researchers found that patients treated with Onivyde plus fluorouracil/leucovorin lived an average of 6.1 months, compared to 4.2 months for those treated with only fluorouracil/leucovorin. However, the researchers observed no survival benefit for patients who received Onivyde alone compared to those who received only fluorouracil/leucovorin.

The average amount of time to tumor growth was 3.1 months for patients who received Onivyde plus fluorouracil/leucovorin, compared to 1.5 months for those who received only fluorouracil/leucovorin.

The most common side effects of Onivyde were diarrhea, fatigue, vomiting, nausea, decreased appetite, stomatitis, and fever, the researchers said. The drug also led to lymphopenia and neutropenia. The FDA said that death due to sepsis following neutropenia has been reported in patients taking Onivyde. Onivyde's label carries a boxed warning about the risks of severe neutropenia and diarrhea.

The drug is marketed by Merrimack Pharmaceuticals, of Cambridge, Mass.

More Information

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease


More in Home

ASTRO: No Survival Benefit for Adding EBT to Brachytherapy

ASTRO: No Survival Benefit for Adding EBT to ...

Addition of external beam therapy doesn't improve five-year progression-free survival in prostate cancer

ASTRO: Fewer Side Effects With IMRT in Cervical, Endometrial CA

ASTRO: Fewer Side Effects With IMRT in Cervical, ...

Patients in conventional radiotherapy arm had more high-level adverse events than those in IMRT arm

Many Doctors Reluctant to Reveal Mental Health Issues

Many Doctors Reluctant to Reveal Mental Health Issues

Perceived stigma, fear of career repercussions hinder treatment, study suggests

is free, fast, and customized just for you!

Already a member?

Sign In Now »